Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
aldosterone
antagonist
cardiovascular disease
diabetic kidney disease
mineralocorticoid receptor
nonsteroidal
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
26
10
2021
received:
12
07
2021
accepted:
01
11
2021
pubmed:
24
11
2021
medline:
10
6
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline-oriented drug therapy for cardiovascular diseases such as chronic heart failure with reduced ejection fraction and resistant hypertension. Currently available steroidal MRAs are efficacious in reducing morbidity and mortality; however, they can be associated with intolerable side effects including hyperkalaemia in everyday clinical practice. Recently, a new class of non-steroidal MRAs (including esaxerenone, AZD9977, apararenone, KBP-5074 and finerenone) have been developed with an improved benefit-risk profile and a novel indication for finerenone for diabetic kidney disease. To better understand the non-steroidal MRAs, this review provides information on the molecular pharmacology as well as relevant current preclinical and clinical data on cardiorenal outcomes. A comparative review of all compounds in the class is discussed with regard to clinical efficacy and safety as well as a perspective outlining their future use in clinical practice. LINKED ARTICLES: This article is part of a themed issue on Emerging Fields for Therapeutic Targeting of the Aldosterone-Mineralocorticoid Receptor Signaling Pathway. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.13/issuetoc.
Substances chimiques
KBP-5074
0
Mineralocorticoid Receptor Antagonists
0
Mineralocorticoids
0
Piperidines
0
Pyrazoles
0
Quinolines
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3220-3234Informations de copyright
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021). Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European Heart Journal, 42, 152-161. https://doi.org/10.1093/eurheartj/ehaa736
Agarwal, R., Rossignol, P., Romero, A., Garza, D., Mayo, M. R., Warren, S., Ma, J., White, W. B., & Williams, B. (2019). Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England), 394, 1540-1550. https://doi.org/10.1016/S0140-6736(19)32135-X
Alexander, S. P., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Coons, L., Fuller, P. J., Korach, K. S., & Young, M. J. (2021). The Concise Guide to PHARMACOLOGY 2021/22: Nuclear hormone receptors. British Journal of Pharmacology, 178(Suppl 1), S246-S263. https://doi.org/10.1111/bph.15540
Alexander, S. P., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., Buneman, O. P., & Catterall, W. A. (2015). The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology, 172, 5729-5743. https://doi.org/10.1111/bph.13347
Alexandrou, M. E., Papagianni, A., Tsapas, A., Loutradis, C., Boutou, A., Piperidou, A., Papadopoulou, D., Ruilope, L., Bakris, G., & Sarafidis, P. (2019). Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: A systematic review and meta-analysis of randomized controlled trials. Journal of Hypertension, 37, 2307-2324. https://doi.org/10.1097/HJH.0000000000002187
Amazit, L., Le Billan, F., Kolkhof, P., Lamribet, K., Viengchareun, S., Fay, M. R., Khan, J. A., Hillisch, A., Lombès, M., Rafestin-Oblin, M. E., & Fagart, J. (2015). Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. The Journal of Biological Chemistry, 290, 21876-21889. https://doi.org/10.1074/jbc.M115.657957
Arai, K., Homma, T., Morikawa, Y., Ubukata, N., Tsuruoka, H., Aoki, K., Ishikawa, H., Mizuno, M., & Sada, T. (2015). Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. European Journal of Pharmacology, 761, 226-234. https://doi.org/10.1016/j.ejphar.2015.06.015
Arai, K., Morikawa, Y., Ubukata, N., Tsuruoka, H., & Homma, T. (2016). CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate/salt-induced hypertensive rats. The Journal of Pharmacology and Experimental Therapeutics, 358, 548-557. https://doi.org/10.1124/jpet.116.234765
Arai, K., Tsuruoka, H., & Homma, T. (2015). CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. European Journal of Pharmacology, 769, 266-273. https://doi.org/10.1016/j.ejphar.2015.11.028
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987). Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science, 237, 268-275. https://doi.org/10.1126/science.3037703
Bakris, G., Pergola, P. E., Delgado, B., Genov, D., Doliashvili, T., Vo, N., Yang, Y. F., McCabe, J., Benn, V., Pitt, B., & BLOCK-CKD Study Group. (2021). Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study. Hypertension, 78(1), 74-81.
Bakris, G., Yang, Y. F., & Pitt, B. (2020). Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial. Hypertension, 76, 144-149. https://doi.org/10.1161/HYPERTENSIONAHA.120.15199
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., Kolkhof, P., Ferreira, A. C., Schloemer, P., Filippatos, G., & FIDELIO-DKD study investigators. (2019). Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. American Journal of Nephrology, 50, 333-344. https://doi.org/10.1159/000503713
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., & Filippatos, G. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. The New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., Kolkhof, P., Joseph, A., Pieper, A., Kimmeskamp-Kirschbaum, N., Ruilope, L. M., & Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. (2015). Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. Jama, 314, 884-894. https://doi.org/10.1001/jama.2015.10081
Bamberg, K., Johansson, U., Edman, K., William-Olsson, L., Myhre, S., Gunnarsson, A., Geschwindner, S., Aagaard, A., Björnson Granqvist, A., Jaisser, F., Huang, Y., Granberg, K. L., Jansson-Löfmark, R., & Hartleib-Geschwindner, J. (2018). Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE, 13, e0193380. https://doi.org/10.1371/journal.pone.0193380
Barbaro, N. R., Kirabo, A., & Harrison, D. G. (2017). A new role of mister (MR) T in hypertension: Mineralocorticoid receptor, immune system, and hypertension. Circulation Research, 120, 1527-1529. https://doi.org/10.1161/CIRCRESAHA.117.310985
Barfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Perez, S., Heckroth, H., Nitsche, A., Ergüden, J. K., Gielen-Haertwig, H., Schlemmer, K. H., & Mittendorf, J. (2012). Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem, 7, 1385-1403. https://doi.org/10.1002/cmdc.201200081
Berger, S., Bleich, M., Schmid, W., Greger, R., & Schutz, G. (2000). Mineralocorticoid receptor knockout mice: Lessons on Na+ metabolism. Kidney International, 57, 1295-1298. https://doi.org/10.1046/j.1523-1755.2000.00965.x
Bertocchio, J. P., Warnock, D. G., & Jaisser, F. (2011). Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney International, 79, 1051-1060. https://doi.org/10.1038/ki.2011.48
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006). Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International, 70, 2116-2123. https://doi.org/10.1038/sj.ki.5001854
Bolignano, D., Palmer, S. C., Navaneethan, S. D., & Strippoli, G. F. (2014). Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews, (4), CD007004. https://doi.org/10.1002/14651858.CD007004.pub3
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., Lackland, D. T., Laffer, C. L., Newton-Cheh, C., Smith, S. M., Taler, S. J., Textor, S. C., Turan, T. N., White, W. B., & American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. (2018). Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension, 72, e53-e90. https://doi.org/10.1161/HYP.0000000000000084
Chow, C. P., Liu, J. R., & Huang, Z. H. (2017). Pharmacological profile of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal disease. Journal of Drug Research and Development, 3(2), 2470-1009. https://doi.org/10.16966/12470-11009.16137
Chow, C. P., Liu, J. R., Tan, X. J., & Huang, Z. H. (2018). Preclinical development of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases. Journal of Drug Research and Development, 4(2), 2470-1009. https://doi.org/10.16966/12470-11009.16143
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020). Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews, (10), CD007004.
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Jüni, P., Lettino, M., Marx, N., Mellbin, L. G., Östgren, C. J., Rocca, B., Roffi, M., … Chowdhury, T. A. (2020). 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 41, 255-323. https://doi.org/10.1093/eurheartj/ehz486
Currie, G., Taylor, A. H., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., & van den Meiracker, A. H. (2016). Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrology, 17, 127. https://doi.org/10.1186/s12882-016-0337-0
de Gasparo, M., Joss, U., Ramjoue, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987). Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro. The Journal of Pharmacology and Experimental Therapeutics, 240, 650-656.
de Gasparo, M., Whitebread, S. E., Preiswerk, G., Jeunemaitre, X., Corvol, P., & Menard, J. (1989). Antialdosterones: Incidence and prevention of sexual side effects. Journal of Steroid Biochemistry, 32, 223-227. https://doi.org/10.1016/0022-4731(89)90169-6
Dutzmann, J., Musmann, R. J., Haertle, M., Daniel, J. M., Sonnenschein, K., Schafer, A., Schäfer, A., Kolkhof, P., Bauersachs, J., & Sedding, D. G. (2017). The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE, 12, e0184888. https://doi.org/10.1371/journal.pone.0184888
Epstein, M. (2015). Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. The Lancet Diabetes and Endocrinology, 3, 993-1003. https://doi.org/10.1016/S2213-8587(15)00289-2
Erlandsson, F., Albayaty, M., Chialda, L., Ericsson, H., Amilon, C., Nelander, K., Jansson-Löfmark, R., Wernevik, L., Kjaer, M., Bamberg, K., & Hartleib-Geschwindner, J. (2018). Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. British Journal of Clinical Pharmacology, 84, 1486-1493. https://doi.org/10.1111/bcp.13562
Fagart, J., Hillisch, A., Huyet, J., Barfacker, L., Fay, M., Pleiss, U., Pook, E., Schäfer, S., Rafestin-Oblin, M. E., & Kolkhof, P. (2010). A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. The Journal of Biological Chemistry, 285, 29932-29940. https://doi.org/10.1074/jbc.M110.131342
Ferreira, N. S., Tostes, R. C., Paradis, P., & Schiffrin, E. L. (2021). Aldosterone, inflammation, immune system, and hypertension. American Journal of Hypertension, 34, 15-27. https://doi.org/10.1093/ajh/hpaa137
Filippatos, G., Anker, S. D., Bohm, M., Gheorghiade, M., Kober, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., & Kim, S. Y. (2016). A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 37, 2105-2114. https://doi.org/10.1093/eurheartj/ehw132
Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., Tasto, C., Joseph, A., Anker, S. D., & FIDELIO-DKD Investigators. (2021). Finerenone reduces onset of atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. Journal of the American College of Cardiology, 78, 142-152. https://doi.org/10.1016/j.jacc.2021.04.079
Fraccarollo, D., Berger, S., Galuppo, P., Kneitz, S., Hein, L., Schütz, G., Frantz, S., Ertl, G., & Bauersachs, J. (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation, 123, 400-408. https://doi.org/10.1161/CIRCULATIONAHA.110.983023
Fuller, P. J., Yang, J., & Young, M. J. (2017). 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Coregulators as mediators of mineralocorticoid receptor signalling diversity. The Journal of Endocrinology, 234, T23-T34. https://doi.org/10.1530/JOE-17-0060
Galigniana, M. D., Piwien Pilipuk, G., Kanelakis, K. C., Burton, G., & Lantos, C. P. (2004). Molecular mechanism of activation and nuclear translocation of the mineralocorticoid receptor upon binding of pregnanesteroids. Molecular and Cellular Endocrinology, 217, 167-179. https://doi.org/10.1016/j.mce.2003.10.041
Gardiner, P., Schrode, K., Quinlan, D., Martin, B. K., Boreham, D. R., Rogers, M. S., Stubbs, K., Smith, M., & Karim, A. (1989). Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites. Journal of Clinical Pharmacology, 29, 342-347. https://doi.org/10.1002/j.1552-4604.1989.tb03339.x
Gerisch, M., Heinig, R., Engelen, A., Lang, D., Kolkhof, P., Radtke, M., Platzek, J., Lovis, K., Rohde, G., & Schwarz, T. (2018). Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metabolism and Disposition, 46, 1546-1555. https://doi.org/10.1124/dmd.118.083337
Grune, J., Benz, V., Brix, S., Salatzki, J., Blumrich, A., Höft, B., Klopfleisch, R., Foryst-Ludwig, A., Kolkhof, P., & Kintscher, U. (2016). Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. Journal of Cardiovascular Pharmacology, 67, 402-411. https://doi.org/10.1097/FJC.0000000000000366
Grune, J., Beyhoff, N., Smeir, E., Chudek, R., Blumrich, A., Ban, Z., Brix, S., Betz, I. R., Schupp, M., Foryst-Ludwig, A., Klopfleisch, R., Stawowy, P., Houtman, R., Kolkhof, P., & Kintscher, U. (2018). Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension, 71, 599-608. https://doi.org/10.1161/HYPERTENSIONAHA.117.10360
Han, S. Y., Kim, C. H., Kim, H. S., Jee, Y. H., Song, H. K., Lee, M. H., Han, K. H., Kim, H. K., Kang, Y. S., Han, J. Y., Kim, Y. S., & Cha, D. R. (2006). Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Journal of the American Society of Nephrology, 17, 1362-1372. https://doi.org/10.1681/ASN.2005111196
Heinig, R., Kimmeskamp-Kirschbaum, N., Halabi, A., & Lentini, S. (2016). Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clinical Pharmacology in Drug Development, 5, 488-501. https://doi.org/10.1002/cpdd.263
Ito, S., Itoh, H., Rakugi, H., Okuda, Y., & Iijima, S. (2021). Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertension Research, 44, 489-497. https://doi.org/10.1038/s41440-020-00585-y
Ito, S., Itoh, H., Rakugi, H., Okuda, Y., & Yamakawa, S. (2019). Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: A phase 2 randomized, placebo-controlled, double-blind study. Journal of Human Hypertension, 33, 542-551. https://doi.org/10.1038/s41371-019-0207-x
Ito, S., Itoh, H., Rakugi, H., Okuda, Y., Yoshimura, M., & Yamakawa, S. (2020). Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension, 75, 51-58. https://doi.org/10.1161/HYPERTENSIONAHA.119.13569
Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T. (2020). Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial. Clinical Journal of the American Society of Nephrology, 15, 1715-1727. https://doi.org/10.2215/CJN.06870520
Jaisser, F., Tan, X., Chi, S., Liu, J., Wang, P., Bush, M., Benn, V., Yang, Y. F., & Zhang, J. (2021). The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with eplerenone in a rat model with mineralocorticoid-induced renal injury. Frontiers in Pharmacology, 12, 604928. https://doi.org/10.3389/fphar.2021.604928
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004). Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. The New England Journal of Medicine, 351, 543-551. https://doi.org/10.1056/NEJMoa040135
Kagawa, C. M., Cella, J. A., & Van Arman, C. G. (1957). Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt. Science, 126, 1015-1016. https://doi.org/10.1126/science.126.3281.1015
Karim, A. (1978). Spironolactone: Disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metabolism Reviews, 8, 151-188. https://doi.org/10.3109/03602537808993782
Karim, A., Zagarella, J., Hribar, J., & Dooley, M. (1976). Spironolactone. I. Disposition and metabolism. Clinical Pharmacology & Therapeutics, 19, 158-169. https://doi.org/10.1002/cpt1976192158
Kolkhof, P., & Barfacker, L. (2017). 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. The Journal of Endocrinology, 234, T125-T140. https://doi.org/10.1530/JOE-16-0600
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014). Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. Journal of Cardiovascular Pharmacology, 64, 69-78. https://doi.org/10.1097/FJC.0000000000000091
Kolkhof, P., Jaisser, F., Kim, S. Y., Filippatos, G., Nowack, C., & Pitt, B. (2017). Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside. Handbook of Experimental Pharmacology, 243, 271-305. https://doi.org/10.1007/164_2016_76
Kolkhof, P., Joseph, A., & Kintscher, U. (2021). Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders-New perspectives for combination therapy. Pharmacological Research, 172, 105859. https://doi.org/10.1016/j.phrs.2021.105859
Lavall, D., Jacobs, N., Mahfoud, F., Kolkhof, P., Bohm, M., & Laufs, U. (2019). The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochemical Pharmacology, 168, 173-183. https://doi.org/10.1016/j.bcp.2019.07.001
Lee, H., Fessler, M. B., Qu, P., Heymann, J., & Kopp, J. B. (2020). Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease. BMC Nephrology, 21, 270. https://doi.org/10.1186/s12882-020-01921-7
Lentini, S., Kimmeskamp-Kirschbaum, N., Wensing, G., & Heinig, R. (2012). Abstract 10732: BAY 94-8862 exerts a potent natriuretic effect in healthy male subjects pre-treated with fludrocortisone: Findings from a proof-of-concept study. Circulation, 126, A10732-A10732.
Leroy, V., De Seigneux, S., Agassiz, V., Hasler, U., Rafestin-Oblin, M. E., Vinciguerra, M., Martin, P. Y., & Feraille, E. (2009). Aldosterone activates NF-κB in the collecting duct. Journal of the American Society of Nephrology, 20, 131-144. https://doi.org/10.1681/ASN.2008020232
Lother, A., Berger, S., Gilsbach, R., Rosner, S., Ecke, A., Barreto, F., Bauersachs, J., Schütz, G., & Hein, L. (2011). Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension, 57, 746-754. https://doi.org/10.1161/HYPERTENSIONAHA.110.163287
McCurley, A., Pires, P. W., Bender, S. B., Aronovitz, M., Zhao, M. J., Metzger, D., Chambon, P., Hill, M. A., Dorrance, A. M., Mendelsohn, M. E., & Jaffe, I. Z. (2012). Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nature Medicine, 18, 1429-1433. https://doi.org/10.1038/nm.2891
McKenna, N. J., & O'Malley, B. W. (2010). SnapShot: Nuclear receptors I. Cell, 142(5), 822-822.
Nakamura, T., & Kawaguchi, A. (2021). Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers. Clinical Pharmacology in Drug Development, 10, 353-365. https://doi.org/10.1002/cpdd.855
Nakamura, T., Shimizu, H., & Kawaguchi, A. (2020). Drug-drug interactions of the nonsteroidal mineralocorticoid receptor antagonist apararenone with midazolam, warfarin, and digoxin: A phase 1 studies in healthy volunteers. Clinical Therapeutics, 42(11), 2171-2183.
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. (2009). Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology, 4, 542-551. https://doi.org/10.2215/CJN.04750908
Parving, H. H., Brenner, B. M., McMurray, J. J., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., & Richard, A. (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. The New England Journal of Medicine, 367, 2204-2213. https://doi.org/10.1056/NEJMoa1208799
Pfeffer, M. A., Claggett, B., Assmann, S. F., Boineau, R., Anand, I. S., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Heitner, J. F., Lewis, E. F., O'Meara, E., Rouleau, J. L., Probstfield, J. L., Shaburishvili, T., Shah, S. J., Solomon, S. D., Sweitzer, N. K., … Pitt, B. (2015). Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation, 131, 34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021). Cardiovascular events with finerenone in kidney disease and type 2 diabetes. The New England Journal of Medicine, 2252-2263. https://doi.org/10.1056/NEJMoa2110956
Pitt, B., Filippatos, G., Gheorghiade, M., Kober, L., Krum, H., Ponikowski, P., Nowack, C., Kolkhof, P., Kim, S. Y., & Zannad, F. (2012). Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure, 14, 668-675. https://doi.org/10.1093/eurjhf/hfs061
Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S. Y., & Zannad, F. (2013). Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. European Heart Journal, 34, 2453-2463. https://doi.org/10.1093/eurheartj/eht187
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O'Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., … McKinlay, S. M. (2014). Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine, 370, 1383-1392. https://doi.org/10.1056/NEJMoa1313731
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine, 348, 1309-1321. https://doi.org/10.1056/NEJMoa030207
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine, 341, 709-717. https://doi.org/10.1056/NEJM199909023411001
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., Falk, V., González-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., … ESC Scientific Document Group. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200. https://doi.org/10.1093/eurheartj/ehw128
Rickard, A. J., Morgan, J., Chrissobolis, S., Miller, A. A., Sobey, C. G., & Young, M. J. (2014). Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension, 63, 1033-1040. https://doi.org/10.1161/HYPERTENSIONAHA.113.01803
Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., Kolkhof, P., Joseph, A., Mentenich, N., Pitt, B., & FIGARO-DKD study investigators. (2019). Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. American Journal of Nephrology, 50, 345-356. https://doi.org/10.1159/000503712
Schwabe, J. W., Chapman, L., Finch, J. T., & Rhodes, D. (1993). The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements. Cell, 75, 567-578. https://doi.org/10.1016/0092-8674(93)90390-C
Takahashi, M., Ubukata, O., Homma, T., Asoh, Y., Honzumi, M., Hayashi, N., Saito, K., Tsuruoka, H., Aoki, K., & Hanzawa, H. (2020). Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS Letters, 594, 1615-1623. https://doi.org/10.1002/1873-3468.13746
Tanenbaum, D. M., Wang, Y., Williams, S. P., & Sigler, P. B. (1998). Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proceedings of the National Academy of Sciences of the United States of America, 95, 5998-6003. https://doi.org/10.1073/pnas.95.11.5998
Trevisan, M., de Deco, P., Xu, H., Evans, M., Lindholm, B., Bellocco, R., Barany, P., Jernberg, T., Lund, L. H., & Carrero, J. J. (2018). Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20, 1217-1226. https://doi.org/10.1002/ejhf.1199
Wada, T., Inagaki, M., Yoshinari, T., Terata, R., Totsuka, N., Gotou, M., & Hashimoto, G. (2021). Apararenone in patients with diabetic nephropathy: Results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clinical and Experimental Nephrology, 25, 120-130. https://doi.org/10.1007/s10157-020-01963-z
Wan, N., Rahman, A., & Nishiyama, A. (2021). Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. Journal of Human Hypertension, 35, 148-156. https://doi.org/10.1038/s41371-020-0377-6
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002). Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension, 15, 709-716. https://doi.org/10.1016/S0895-7061(02)02957-6
Whittaker, A., Kragh, A. M., Hartleib-Geschwindner, J., Albayaty, M., Backlund, A., Greasley, P. J., Heijer, M., Kjaer, M., Forte, P., Unwin, R., Wernevik, L., & Ericsson, H. (2020). Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: A phase I multiple ascending dose study. Clinical and Translational Science, 13, 275-283. https://doi.org/10.1111/cts.12705
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., Mackenzie, I., Padmanabhan, S., Brown, M. J., & British Hypertension Society's PATHWAY Studies Group. (2015). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet (London, England), 386, 2059-2068. https://doi.org/10.1016/S0140-6736(15)00257-3
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., … Brady, A. (2018). 2018 ESC/ESH guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, 39, 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Yamada, M., Mendell, J., Takakusa, H., Shimizu, T., & Ando, O. (2019). Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metabolism and Disposition, 47, 340-349. https://doi.org/10.1124/dmd.118.084897
Yao, L., Wright, M. F., Farmer, B. C., Peterson, L. S., Khan, A. M., Zhong, J., Gewin, L., Hao, C. M., Yang, H. C., & Fogo, A. B. (2019). Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology, Dialysis, Transplantation, 34, 2042-2050. https://doi.org/10.1093/ndt/gfz050
Zannad, F., McMurray, J. J., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine, 364, 11-21. https://doi.org/10.1056/NEJMoa1009492